PROGRAM 4 (CLINICAL AND EXPERIMENTAL THERAPEUTICS)

计划 4（临床和实验治疗）

• 批准号: 7714258
• 负责人: EVERETT E. VOKES
• 金额: $ 2.54万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-22 至 2013-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7714258
• 关键词: Antineoplastic Agents; Cancer Patient; Cancer and Leukemia Group B; Chemistry; Chicago; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Clinical Trials Design; Collaborations; Combined Modality Therapy; Conduct Clinical Trials; Cytostatics; Cytotoxic agent; Development; Direct Costs; Drug Kinetics; End Point; Enrollment; Faculty; Fostering; Funding; Genotype; Goals; Grant; Image; Laboratory Study; Leadership; Malignant Neoplasms; Measurement; Medical Oncology; Medicine; Nature; Operative Surgical Procedures; Organ Preservation; Pathology; Patients; Peer Review; Pharmaceutical Preparations; Pharmacogenetics; Pharmacogenomics; Pharmacology; Phase; Phase I Clinical Trials; Phase II Clinical Trials; Phase III Clinical Trials; Population Study; Portugal; Program Development; Protocols documentation; Publications; Radiation Oncology; Rate; Research Personnel; Role; Solid Neoplasm; Surgical Pathology; Surgical Specialties; Surrogate Endpoint; Therapeutic; Therapeutic Agents; Transplantation; Universities; Work; chemotherapy; concept; drug development; gene-radiation therapy; innovation; member; multidisciplinary; novel; oncology; pre-clinical; programs; research clinical testing; response

The Clinical and Experimental Therapeutics Program (Program 4) is a cohesive, integrated program supported by $7,523,204 (annual direct costs) in peer-reviewed funding, with $3,613,675 from the NCI. There are 47 members representing nine departments. Of the total 747 member peer-reviewed publications during the current grant cycle, 216 (29%) represent intraprogrammatic, and 145 (19%) represent interprogrammatic collaborations. The overall goal of the Program is to foster interaction between basic and clinical investigators that will result in innovative and effective therapies for cancer patients. The translational nature of much of the work emanating from this program and the leadership role assumed by many program faculty in studies conducted by national clinical trials cooperative groups illustrates the impact of this program in developing new therapies for oncology. The Program has a long-standing focus on drug development at all phases of clinical testing and a strong pharmacogenetic component. Trials span the gamut from preclinical development to investigator-initiated Phase I clinical trials, to Phase II trials in the regional Phase II network to Phase III studies within CALGB. They incorporate correlative laboratory studies including pharmacokinetic studies, genotyping studies, population pharmacology, pharmacogenetic studies, and the measurement of surrogate endpoints. Clinical trials are conducted by multidisciplinary teams comprised of a group of clinical investigators representing Medical Oncology, Radiation Oncology, Pathology, and appropriate surgical specialties. Clinical efforts focus on studies of new drugs (cytotoxic or cytostatic) with clinical and translational endpoints, modulation of current chemotherapy, sequencing of multidisciplinary treatment, organ preservation, transplantation, and treatment intensification as strategies to increase cure rates and response. Imaging, surgical, and pathology support are integrated into the Program. The scientific goals are (1) to foster interaction between basic and clinical investigators that will result in innovative and effective therapies; (2) to integrate new drugs into the development of multimodality therapies for patients with advanced solid tumors; and (3) to pursue a broad program of preclinical, translational, and clinical research in pharmacogenetics and pharmacology.

临床和实验治疗学计划（计划4）是一个有凝聚力的综合计划 由7，523，204美元（年度直接费用）的同行评审资金支持，其中3，613，675美元来自NCI。 有47名成员代表9个部门。在747篇成员同行评审出版物中， 在当前的赠款周期，216（29%）是计划内的，145（19%）是计划外的。 方案间合作。 该计划的总体目标是促进基础和临床研究者之间的互动， 为癌症患者提供创新和有效的治疗方法。大部分作品的翻译性质 从这个程序和许多程序教师在研究中承担的领导作用产生 由国家临床试验合作小组进行的研究表明，该计划在发展中国家的影响， 肿瘤学的新疗法该计划长期以来一直关注药物开发的各个阶段， 临床试验和强大的药物遗传学成分。临床试验涵盖了从临床前 发展到制药商启动的I期临床试验，发展到区域II期网络中的II期试验 在CALGB中进行III期研究。它们结合了相关的实验室研究，包括药代动力学 研究、基因分型研究、群体药理学、药物遗传学研究和 替代终点。临床试验由多学科团队进行，该团队由一组临床 代表内科肿瘤学、放射肿瘤学、病理学和适当外科手术的研究者 特产临床工作重点是研究具有临床和生物学效应的新药（细胞毒性或细胞抑制性）， 转化终点，当前化疗的调整，多学科治疗的排序， 器官保存、移植和强化治疗作为提高治愈率的策略， 反应成像，手术和病理支持被集成到该计划。 科学目标是（1）促进基础和临床研究者之间的互动， 创新和有效的治疗方法;（2）将新药纳入多模态开发 晚期实体瘤患者的治疗;和（3）进行广泛的临床前， 药物遗传学和药理学的转化和临床研究。